Formulation, Development and in-Vitro Evaluation of Rabeprazole Sodium Delayed Release Enteric Coated Tablets

Abstract

Rabeprazole sodium is a proton pump inhibitor used to treat peptic ulcer, duodenal ulcer, gastro oesophageal reflux disease by inhibiting the enzyme H + /K + ATPase, the acidic pump. It is also used to treatZollinger-Ellison syndrome, erosive esophagitis.This study is aimed to develop pharmaceutically equivalent and stable enteric-coated tablets of Rabeprazole sodium which protects it from acidic environment of the stomach. Six Formulations of Rabeprazole core tablets were developed using mannitol as diluents, crospovidone and polyplasdone-XL as super disintegrants, sodium carbonate anhydrous as stabilizer, magnesium stearate and talc as lubricant and glidant in different proportions, and the prepared core tablets were coated with enteric coating using hypromellose phthalate 55, myvacet, pigment blend yellow, ethanol and purified water. Compatibility studies were performed for drug, physical mixture tablet which shows no interaction. From the dissolution the formulation F6 shows highest percentage of drug release.